Institution
Sunovion
Company•London, United Kingdom•
About: Sunovion is a company organization based out in London, United Kingdom. It is known for research contribution in the topics: Lurasidone & Placebo. The organization has 572 authors who have published 1022 publications receiving 18488 citations. The organization is also known as: Sunovion Pharmaceuticals, Inc..
Topics: Lurasidone, Placebo, Population, Eszopiclone, Atypical antipsychotic
Papers published on a yearly basis
Papers
More filters
••
TL;DR: Nebulized GLY improved lung function and health status and was well tolerated over 12 weeks in patients with moderate-to-very-severe COPD, irrespective of baseline disease severity and age.
Abstract: Background The efficacy and safety of nebulized glycopyrrolate inhalation solution (GLY), administered twice daily (BID) via the innovative eFlow® Closed System nebulizer (PARI Pharma GmbH, Starnberg, Germany), were demonstrated in two replicate, placebo-controlled, 12-week Phase III studies (GOLDEN 3 and GOLDEN 4). This report evaluates the efficacy and safety of GLY by baseline disease severity and age in the pooled GOLDEN 3 and GOLDEN 4 patient population (N=1,294). Methods Patients were grouped by baseline predicted post-bronchodilator FEV1 (<50%, ≥50%) and age (<65, ≥65, ≥75 years). Results GLY (25 and 50 μg BID) produced significant improvements in trough FEV1 in FEV1% predicted <50% (0.070 L, 0.079 L) and ≥50% (0.112 L, 0.126 L) subgroups (P<0.01 vs placebo), and in patients aged <65 (0.056 L, 0.086 L), ≥65 (0.140 L, 0.124 L), and ≥75 (0.144 L, 0.120 L) years (P<0.05 vs placebo). St George's Respiratory Questionnaire (SGRQ) total score was significantly improved with GLY 25 and 50 μg BID (P<0.05 vs placebo) in FEV1% predicted <50% (-3.237, -3.061) and ≥50% (-3.392, -2.322) and in <65 years (-3.447, -2.318) and ≥65 years (-3.053, -3.098) subgroups. In patients aged ≥75 years, GLY 25 μg reduced SGRQ total score by -6.278 units (P<0.01 vs placebo). The incidence of treatment-emergent adverse events was similar between GLY and placebo across all subgroups, and the overall incidence of cardiovascular events was low. Conclusions Nebulized GLY improved lung function and health status and was well tolerated over 12 weeks in patients with moderate-to-very-severe COPD, irrespective of baseline disease severity and age. Clinical trial registration NCT02347761, NCT02347774.
6 citations
•
07 Feb 2005TL;DR: In this article, the authors present pharmaceutical compositions comprising a dopamine agonist and a sedative agent for the treatment of restless-leg syndrome and periodic-limb-movement disorder, as well as various sleep disorders.
Abstract: The present invention generally to pharmaceutical compositions comprising a dopamine agonist and sedative agent. In a preferred embodiment, the dopamine agonist is optically pure (S)-didesmethylsibutramine. In a preferred embodiment, the sedative agent is optically pure (S)-zopiclone or optically pure (S)-N-desmethylzoplicone. The pharmaceutical compositions of the invention are useful in the treatment of restless-leg syndrome and periodic-limb-movement disorder, as well as various sleep disorders.
6 citations
•
18 Jun 1999TL;DR: In this article, a set of tetrapeptides, analogs, peptidomimetics and pharmaceutical preparations thereof that bind selectively to mammalian opioid receptors are presented. But the present set of compounds comprises full agonists, partial agonists and antagonists.
Abstract: The present invention provides tetrapeptides, analogs, peptidomimetics and pharmaceutical preparations thereof, that bind selectively to mammalian opioid receptors. The present set of compounds comprises full agonists, partial agonists, and antagonists of mammalian opioid receptors.
6 citations
••
TL;DR: To evaluate cutaneous allergic reactions in clinical trials of adjunctive eslicarbazepine acetate (ESL) for focal seizures.
Abstract: Objectives To evaluate cutaneous allergic reactions in clinical trials of adjunctive eslicarbazepine acetate (ESL) for focal seizures. Materials and methods Data were analyzed from three phase III randomized, double-blind, placebo-controlled studies of adjunctive ESL in adults (placebo, n = 426; ESL, n = 1021) and two randomized, double-blind, placebo-controlled studies (and open-label extensions [OLEs]) of adjunctive ESL in children aged 4-17 years (placebo, n = 160; ESL, n = 202; OLE, n = 337). Results Adult studies: Rash (ESL 1.9%, placebo 0.9%) and pruritus (ESL 1.2%, placebo 0.9%) were the most frequent rash-related treatment-emergent adverse events (TEAEs). Most rash-related TEAEs were mild or moderate in severity. Incidence of rash increased with increasing ESL dose, but was not higher for patients who initiated treatment with higher ESL doses. Pediatric studies: Allergic dermatitis (ESL 3.0%, placebo 0) and rash (controlled studies: ESL 1.0%, placebo 1.3%; OLE periods: ESL ≤1.2%) were the most frequent rash-related TEAEs. There was one case of DRESS in the ESL group. Most rash-related TEAEs were mild or moderate in severity and judged as not related to treatment with ESL. Conclusions Serious skin rashes were rare during adult and pediatric clinical trials of ESL. Although the incidence of rash with ESL was low, it is important for patients/caregivers to be made aware of the potential signs and symptoms associated with serious skin rashes.
6 citations
•
12 Sep 1989TL;DR: In this article, a method for converting a diastereomeric mixture of S-protected derivatives of an orally active inhibitor of an angiotensin-converting enzyme (ACE) and its analogues into its separate optically resolved diastereric components was proposed.
Abstract: This invention relates to novel methods for converting a diastereomeric mixture of S-protected derivatives of an orally active inhibitor of an angiotensin-converting enzyme (ACE) and its analogues into its separate optically resolved diastereomeric components. Specifically the invention relates to methods for the preparation of optically purified captopril and its analogs from racemic precursors. This resolution process is achieved through the fractional crystallization of S-protected derivatives of captopril and its precursors, which derivatives are useful for the reason that they are (1) easily prepared from novel precursors, (2) resolvable to their optically purified stereoisomeric species and (3) convertible to non-derivatized stereoisomeric species which correspond to the pharmacologically active inhibitor and its analogues. Novel methods for preparing the derivatives and their precursors are also noted herein. In addition, the novel derivatives and their precursors are also described herein.
6 citations
Authors
Showing all 572 results
Name | H-index | Papers | Citations |
---|---|---|---|
Chris H. Senanayake | 58 | 588 | 12142 |
Paul J. Reider | 55 | 344 | 9827 |
Antony Loebel | 42 | 223 | 6906 |
Kenneth S. Koblan | 40 | 96 | 4380 |
Richard G. Ball | 37 | 142 | 3684 |
Robert D. Larsen | 36 | 147 | 3544 |
Robert Goldman | 35 | 110 | 7064 |
Raymond L. Woosley | 34 | 115 | 3811 |
Rudy Schreiber | 33 | 80 | 3793 |
Thomas R. Verhoeven | 29 | 127 | 3135 |
Andrei Pikalov | 28 | 120 | 2583 |
David Blum | 27 | 89 | 2958 |
Mark A. Varney | 26 | 41 | 4032 |
Lisa DiMichele | 25 | 88 | 1755 |
John P. Hanrahan | 25 | 46 | 2781 |